These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 28668492)

  • 21. [Clinical analysis of acute renal failure after allogeneic hematopoietic stem cell transplantation].
    Zhou T; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Wang LH; Tong YJ; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):723-8. PubMed ID: 19549395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center.
    Linke C; Tragiannidis A; Ahlmann M; Fröhlich B; Wältermann M; Burkhardt B; Rossig C; Groll AH
    Mycoses; 2019 Oct; 62(10):954-960. PubMed ID: 31332851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation.
    Linke C; Ehlert K; Ahlmann M; Fröhlich B; Mohring D; Burkhardt B; Rössig C; Groll AH
    Mycoses; 2020 Feb; 63(2):172-180. PubMed ID: 31661569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
    McCoy D; Depestel DD; Carver PL
    Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The prevalence and risk factors of invasive fungal infection in hematopoietic stem cell transplant recipients].
    Xu LP; Ji Y; Liu DH; Chen YH; Han W; Liu KY; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):486-9. PubMed ID: 17663826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for invasive mold diseases in allogeneic hematopoietic cell transplant recipients.
    Atalla A; Garnica M; Maiolino A; Nucci M
    Transpl Infect Dis; 2015 Feb; 17(1):7-13. PubMed ID: 25573063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia].
    Chen Y; Xu LP; Liu KY; Liu DH; Han W; Chen H; Zhang YC; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Apr; 47(4):316-9. PubMed ID: 18843958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
    Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
    Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation.
    Sahin U; Toprak SK; Atilla PA; Atilla E; Demirer T
    J Infect Chemother; 2016 Aug; 22(8):505-14. PubMed ID: 27344206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients.
    Piñana JL; Gómez MD; Montoro J; Lorenzo I; Pérez A; Giménez E; González-Barberá EM; Carretero C; Guerreiro M; Salavert M; Sanz G; Hernández-Boluda JC; Borrás R; Sanz J; Solano C; Navarro D
    Transpl Infect Dis; 2019 Oct; 21(5):e13158. PubMed ID: 31402532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Gao L; Sun Y; Meng F; Han M; Huang H; Wu D; Yu L; Ren H; Huang X; Zhang X
    J Hematol Oncol; 2016 Sep; 9(1):97. PubMed ID: 27663309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: A single-center study in Québec, Canada.
    Lavallée C; Labbé AC; Talbot JD; Alonso CD; Marr KA; Cohen S; Laverdière M; Dufresne SF
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
    Marty FM; Lee SJ; Fahey MM; Alyea EP; Soiffer RJ; Antin JH; Baden LR
    Blood; 2003 Oct; 102(8):2768-76. PubMed ID: 12855583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic stem cell transplant recipients with prior pulmonary aspergillosis.
    Liu Q; Lin R; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Fan Z; Zhou H; Jiang Q; Zhang F; Zhai X; Xu D; Wei Y; Song J; Li Y; Feng R
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1198-203. PubMed ID: 24769013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years.
    Shi JM; Pei XY; Luo Y; Tan YM; Tie RX; He JS; Zheng WY; Zhang J; Cai Z; Lin MF; Huang H
    J Zhejiang Univ Sci B; 2015 Sep; 16(9):796-804. PubMed ID: 26365122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.
    Garcia-Vidal C; Upton A; Kirby KA; Marr KA
    Clin Infect Dis; 2008 Oct; 47(8):1041-50. PubMed ID: 18781877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
    Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
    Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
    Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
    Modi A; Rybicki L; Majhail NS; Mossad SB
    Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.